Patients with Breast Symptoms g*BRCA* Testing Pathway

This pathway has been produced and funded by AstraZeneca as part of a steering committee, and reviewed and agreed in collaboration with UK Breast Cancer Group (UKBCG), Association of Breast Surgery (ABS), and UK Clinical Genetics Group (UKCGG)



National genomic test directory - Version 7 July 2024

R208 Inherited breast cancer and ovarian cancer

a. Breast cancer (age <40 years), OR
b. Bilateral breast cancer (age < 60 years), OR
c. Triple negative breast cancer (age < 60 years), OR
d. Male breast cancer (any age), OR
e. Breast cancer (age <45 years) and a first degree relative with breast cancer (age <45 years), OR
f. Combined pathology-adjusted Manchester score ⩾ 15 or single gene pathology adjusted score of ⩾10 or BOADICEA/CanRisk score ⩾10%, OR
g. Ashkenazi Jewish ancestry and breast cancer at any age
h. ⩾ 1 grandparent from Westray (Orkney) or Whalsay (Shetland) and breast cancer at any age

R444.1 NICE approved PARP inhibitor treatment

1. For people with triple negative breast cancer who have received neo-adjuvant chemotherapy:
   - residual invasive cancer in the breast, the resected lymph nodes (non-pathological complete response) or both at the time of surgery
2. For people with triple-negative breast cancer having adjuvant chemotherapy:
   - node-positive OR
   - node-negative cancer with a primary tumour ⩾ 2 cm
3. For people with hormone receptor-positive, HER2-negative breast cancer who have received neoadjuvant chemotherapy:
   - residual invasive cancer in the breast, the resected lymph nodes (non-pathologic complete response) or both at the time of surgery, AND a CPS + EG score of ⩾3 based on pre-treatment clinical and posttreatment pathological stage, receptor status and histological grade
4. For people with hormone receptor-positive, HER2-negative breast cancer having adjuvant chemotherapy:
   - 4 or more pathologically confirmed positive lymph nodes
5. For people who have HER2-negative locally advanced or metastatic breast cancer:
   - Patients should have been previously treated with an anthracycline and/or a taxane in the neo/adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments
   - Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy

Please consult the Test Directory Rare & Inherited disease for a complete list of supported criteria and list of overlapping indications.

Reference: https://www.england.nhs.uk/publication/national-genomic-test-directories/
Accessed January 2025

GB-61949
Date of Preparation: January 2025